Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data - Pfizer (NYSE:PFE)

Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data - Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. Phase 3 BASIS study in patients without inhibitors supported the FDA approval of Hympavzi in October 2024. The study met the primary endpoint and key secondary bleeding endpoints, demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key …

Hympavzi lowers bleeding rates for hemophilia patients: Trial data

Preventive treatment with Hympavzi (marstacimab-hncq) can effectively reduce bleeding rates in people with hemophilia A or B who have inhibitors, or antibodies against standard replacement therapies, according to top-line data from a Phase 3 clinical trial. Hympavzi’s developer Pfizer said it’s now planning to discuss these data with regulatory authorities in hopes of getting the prophylactic (preventive) therapy approved for hemophilia patients…

Pfizer reports positive results from Phase III BAISIS trial for haemophilia

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.The post Pfizer reports positive results from Phase III BAISIS trial for haemophilia appeared first on Clinical Trials Arena.

Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in ...